In the Curtis dataset, which contains microarray data for 1508 ER+ breast cancer patients [39], we stratified ER+ breast cancer patients into a good (alive after 10 years) and poor (death due to disease before 10 years) prognosis group with 387 and 293 patients, respectively. This evidence concerns the gene ESR1 and breast cancer.